(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
PERSEVERE is a multi-biomarker-based risk model to predict outcome and illness severity for individual children with septic shock. The candidate stratification biomarkers have been selected in a systematic and unbiased manner using our gene expression database. The model was derived and validated in collaboration with Christopher Lindsell, PhD, The serum candidate biomarkers are measured using a multiplex platform developed in collaboration with the Millipore Corp. PERSEVERE was funded by an American Recovery and Reinvestment Act Challenge Grant sponsored by the National Heart, Lung and Blood Institute.
We have also received an Innovation Fund Award from the Cincinnati Children's Center for Technology Commercialization.
List of candidate stratification biomarkers for PERSEVERE.
We have also adapted PERSEVERE for use in adults with severe sepsis and septic shock. The adult version of PERSEVERE is called ASSIST (Adult Septic Shock Information and Stratification Technology). ASSIST was developed in collaboration with investigators from the Centre for Heart Lung Innovation, University of British Columbia and St. Paul’s Hospital, the FINNSepsis Study Group, and the University of Pennsylvania.
In collaboration with the Center for Acute Care Nephrology at Cincinnati Children’s, we have recently derived a list of 21 candidate genes to predict persistent, severe, septic shock-associated kidney injury within 24 hours of admission to the pediatric intensive care unit. These 21 genes are being further explored to identify serum-based biomarkers for septic shock associated kidney injury via a recently awarded grant from the National Institutes of Health.
Twenty-one candidate stratification genes for predicting septic shock-associated kidney injury.
Using unsupervised hierarchical clustering, we have identified three subclasses of children with septic shock based exclusively on differential patterns of gene expression. We then interrogated the clinical database and found that one of the three subclasses had a substantially higher level of illness severity, degree of organ failure and mortality, compared to the other two subclasses. Subsequently, the subclass-defining gene signature was distilled to a 100-gene expression signature and depicted using gene expression mosaics that give microarray data a “face” that allows for intuitive pattern recognition (The Gene Expression Dynamics Inspector (GEDI)). Clinicians without formal bioinformatics training were able to reliably allocate patients to the correct subclasses. In a subsequent study, we validated the existence of these clinically relevant subclasses in a formal, separate validation cohort of children with septic shock. We are currently exploring the feasibility of bringing this classification to the bedside in the form of a rapid, clinician-friendly readout.
Recently, we derived and validated an updated approach to this subclassification method by employing a digital mRNA quantification platform capable of generating actionable data in a time frame that meets the time constraints of decision making in the intensive care unit. This new approach has theranostic implications for critical care medicine.
The one-hundred subclass-defining genes.
GEDI mosaics demonstrating the three gene expression-based septic shock subclasses.
We recently identified interleukin-27 (IL-27) as a novel biomarker to predict bacterial infection in critically ill children. IL-27 was discovered using our extensive gene expression database, and in our initial derivation cohort it outperformed procalcitonin, which is currently one of the most widely used clinical biomarkers for infection. We have extended these studies to adults in collaboration with investigators in France and the University of California San Francisco.
Wong, H.R., K.D. Liu, K.N. Kangelaris, P. Lahni, and C.S. Calfee. Performance of interleukin-27 as a sepsis diagnostic biomarker in critically ill adults. J Crit Care. 29:718-722, 2014.
Wong, H.R., C.J. Lindsell, P. Lahni, K.W. Hart, and S. Gibot. Interleukin-27 as a sepsis diagnostic biomarker in critically ill adults. Shock. 40:382-386, 2013.
Wong H.R., N.Z. Cvijanovich, M. Hall, G.L. Allen, N.J. Thomas, R.J. Freishtat, N. Anas, K. Meyer, P.A. Checchia, R. Lin, M.T. Bigham, A. Sen, J. Nowak, M. Quasney, J.W. Henricksen, A. Chopra, S. Banschbach, E. Beckman, K. Harmon, P. Lahni, and T.P. Shanley. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care. 16:R213, 2012.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.